Heart-Kidney drug combo study halted early
NCT ID NCT06639087
First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 28 times
Summary
This study tested whether adding a new drug called AZD5462 to the standard medicine dapagliflozin could help people with both heart failure and moderate kidney disease. The trial was stopped early and only included 8 participants. The main goal was to see how the drug combination affected sodium excretion and safety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Research Site
Sofia, 1612, Bulgaria
Conditions
Explore the condition pages connected to this study.